DARÉ Bioscience

158 articles about DARÉ Bioscience

• Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs

  11/20/2023

  Daré Bioscience, Inc. and Premier Research International, LLC announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclusive basis contract research organization services within the United States to support the clinical development of Daré’s reproductive health portfolio.

• Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

  11/13/2023

  Daré Bioscience, Inc. today announced that an overview of the preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream.

• Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

  11/9/2023

  Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2023 and provided a company update.

• Daré Bioscience to Participate in Three November 2023 Conferences

  11/6/2023

  Daré Bioscience, Inc., a leader in women’s health innovation, announced that the company’s President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will participate in the following conferences in November 2023.

• Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023

  11/2/2023

  Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results for the quarter ended September 30, 2023 and to provide a company update.

• Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

  11/1/2023

  Daré Bioscience, Inc., a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC, a Cambridge, MA based novel topical drug delivery company, announced additional positive findings based on further analyses of data from the exploratory Phase 2b RESPOND study that evaluated Sildenafil Cream, 3.6% in women with female sexual arousal disorder.

• Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older

  10/16/2023

  Daré Bioscience, Inc. announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] vaginal gel, 2% in connection with the first commercial sale of the product in the United States, triggering a $1.8 million milestone payment to Daré under its global license agreement with Organon.

• Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

  9/21/2023

  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s investigational contraceptive DARE-LARC1.

• Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting

  9/20/2023

  Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American Menopause Society, or NAMS) taking place September 27-30, 2023 at the Marriott Downtown in Philadelphia, PA.

• Daré Bioscience to Participate in Upcoming Investor Conferences

  9/6/2023

  Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following investor conferences in September 2023.

• Daré Bioscience Completes Previously Announced Equity Financing

  9/5/2023

  Daré Bioscience, Inc. today announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rules with an institutional investor and an investor affiliated with the licensor of one of the company’s early stage product candidates.

• Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

  8/10/2023

  Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended June 30, 2023, and provided a company update.

• Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

  8/9/2023

  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of positive preliminary efficacy results from its Phase 1/2 clinical study of DARE-HRT1 in healthy postmenopausal women.

• Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

  8/3/2023

  Daré Bioscience, Inc., a leader in women’s health innovation, announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update.

• Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth

  7/31/2023

  Daré Bioscience, Inc. today announced it was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) in the amount of approximately $385,000 to support activities related to the conduct and completion of proof-of-concept target validation studies in support of a potential new approach for the prevention and treatment of idiopathic preterm birth.

• Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems

  7/11/2023

  Daré Bioscience, Inc. (NASDAQ: DARE) today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of the 9th Annual International Symposium of Drug Delivery Systems being held July 12-14, 2023, in Amsterdam, the Netherlands.

• Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

  7/11/2023

  Daré Bioscience, Inc. today announced additional positive data from the exploratory Phase 2b RESPOND study evaluating topical Sildenafil Cream, 3.6% (Sildenafil Cream) as a treatment for female sexual arousal disorder (FSAD).

• Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

  7/6/2023

  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a virtual Key Opinion Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT.

• Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel

  7/5/2023

  Daré Bioscience, Inc. today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and announced that Organon will pay Daré $1.0 million in July 2023.

• Daré Bioscience Announces Publication in Menopause

  6/21/2023

  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause.